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Plasmodium falciparum is the most virulent humanmalaria parasite because of its ability to cytoadhere in the microvasculature.
Nonhuman primate studies demonstrated relationships among knob expression, cytoadherence, and infectivity. This has not
been examined in humans. Cultured clinical-grade P. falciparum parasites (NF54, 7G8, and 3D7B) and ex vivo-derived cell
banks were characterized. Knob and knob-associated histidine-rich protein expression, CD36 adhesion, and antibody recogni-
tion of parasitized erythrocytes (PEs) were evaluated. Parasites from the cell banks were administered to malaria-naive human
volunteers to explore infectivity. For the NF54 and 3D7B cell banks, blood was collected from the study participants for in vitro
characterization. All parasites were infective in vivo. However, infectivity of NF54 was dramatically reduced. In vitro character-
ization revealed that unlike other cell bank parasites, NF54 PEs lacked knobs and did not cytoadhere. Recognition of NF54 PEs
by immune sera was observed, suggesting P. falciparum erythrocyte membrane protein 1 expression. Subsequent recovery of
knob expression and CD36-mediated adhesion were observed in PEs derived from participants infected with NF54. Knobless cell
bank parasites have a dramatic reduction in infectivity and the ability to adhere to CD36. Subsequent infection of malaria-naive
volunteers restored knob expression and CD36-mediated cytoadherence, thereby showing that the human environment can
modulate virulence.
Plasmodium falciparum is the most virulent of the six Plasmo-dium sp. parasites that infect humans. Its ability to cytoadhere
and sequester itself in the microvasculature can result in ob-
struction of blood flow and organ dysfunction, and these are key
processes in the development of severe falciparum malaria (1).
Parasite cytoadherence and sequestration are facilitated by
parasite-encoded knoblike structures that first appear on early
trophozoite-stage parasites and are formed beneath the plasma
membrane of parasitized erythrocytes (PEs) (2). Cytoadherence
to receptors in the deep vasculature prevents removal and destruc-
tion of the parasite by the mononuclear phagocytic system, espe-
cially the spleen. Higher knob densities have been reported on PEs
collected directly from patients than on cultured PEs infected in
vitro (3). Following in vitro cultivation of P. falciparum, knob for-
mation on PEs varies in an isolate-dependentmanner (3–5), rang-
ing from a mild reduction in density to complete ablation. The
major structural protein in knobs is the knob-associated histidine-
rich protein (KAHRP) (2, 6, 7). Deletion of the gene encoding
KAHRP results in the loss of knobs (8, 9).
P. falciparum isolates can lose the ability to adhere to tissue
receptors in vitro (10). Loss of adherence is isolate dependent and
can occur independently of whether the knob phenotype is re-
tained (10). Cytoadherence involves an interaction between par-
asite ligands and tissue receptors, including CD36, on the vascular
endothelium (11, 12). The principal parasite adhesin is P. falcipa-
rum erythrocytemembrane protein 1 (PfEMP1) (13), an antigeni-
cally variant product of the var gene family that is expressed on the
surface of late-stage PEs and is concentrated on knobs (14–16).
Knobless parasites continue to express PfEMP1 (17, 18) and have
been shown to cytoadhere in static assays (17, 19, 20). However,
under physiologic flow conditions, the ability of knob- and
KAHRP-negative parasites to bind to tissue receptors is signifi-
cantly reduced (7). A reduction in the amount of PfEMP1 dis-
played on the surface of knobless PEs in vitro has been reported
(21).
Knobby and knobless parasites have been examined in nonhu-
man primates (22–24). Knobby clones were more virulent than
knobless clones in nonsplenectomized monkeys (22, 23). Knob-
less P. falciparum parasites were rapidly cleared from the circula-
tion, unlike knob-expressing parasites, an observation attribut-
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able to the parasite’s ability to sequester itself and replicate
without clearance (23). In contrast, in splenectomized monkeys,
this knobless clone showed virulence and did not sequester. A
knob-positive phenotypewas stable in vivo andwas not affected by
the presence of the spleen (23). Infection of splenectomizedmon-
keys with knobby P. falciparum parasites can result in either loss of
knobs (22) or loss of cytoadherence in the presence of knobs (25).
Cytoadherence could be restored when parasites from splenecto-
mized animals were subsequently transferred into animals with
intact spleens (25). The effect of the spleen on cytoadherence may
reflect a fitness cost to the parasite. This is supported by the ob-
servation that sequential passage of P. knowlesi in splenectomized
monkeys resulted in loss of agglutinability of PEs (26) and a re-
duction in variant surface antigen expression (24). Together, these
simian studies demonstrate that knob expression and the ability to
cytoadhere can be variable and affect parasite infectivity.
In humans, knobby and knobless cytoadherent P. falciparum
parasites have been derived from splenectomized patients (27,
28). However, the relationship between knob expression, an ad-
herent phenotype, and infectivity of P. falciparum has not been
investigated. Controlled humanmalaria infection (CHMI) ofma-
laria-naive human volunteers provides an opportunity to investi-
gate this. CHMI can be undertaken by three means: allowing lab-
oratory-reared Plasmodium-infected mosquitoes to feed on
study participants (29–32), injecting cryopreserved sporozo-
ites (33–36), or injecting PEs (37–40). We have recently under-
taken the current good manufacturing practice production of
clinical-grade cultured P. falciparum blood-stage cell banks (41).
While evaluating the safety and infectivity of these cell banks in
malaria-naive volunteers, we demonstrated that although knob-
less parasites have the ability to grow normally in vitro, they have a
dramatic reduction in infectivity in vivo, mirroring a similar re-
duction in the ability to cytoadhere to CD36 in vitro. Of note, in
vivo infection in malaria-naive volunteers restored the expression
of knobs and cytoadherence, thus demonstrating a major role for
the human environment in the modulation and reprogramming
of parasite virulence.
MATERIALS AND METHODS
Clinical studies. Studies 1 and 2 were conducted at the Gold Coast Hos-
pital, Southport, QLD, Australia; study 3 was conducted at Griffith Uni-
versity, Southport, QLD, Australia; and studies 4 and 5 were conducted at
Q-Pharm, Brisbane,QLD,Australia. Study participantswere healthymale
Caucasians 18 to 45 years old. Key eligibility criteria are listed for each
study at the Australian New Zealand Clinical Trials Registry (www.anzctr
.org.au; study reference numbers are provided below). Two volunteers
were enrolled in each study with a delay of2 days between the inocula-
tions of participants 1 and 2 in each group.
If clinical or parasitological evidence of malaria (identification of2
malaria parasites on a malaria thick film, a platelet count of 100 
109/liter, or the onset of clinical features of malaria) was found or the
parasitemia threshold defined in the study protocol was reached, antima-
laria treatment was initiated. For study 1, antimalaria treatment was ini-
tiated as stipulated by the study protocol, despite the lack of parasite
growth. Treatment of malaria entailed the administration of artemether-
lumefantrine (A/L) according to its approved dosing schedule.
Adverse events (abnormal laboratory values, clinical signs or symp-
toms) were monitored either via telephone or at the clinical sites and
graded in severity by experienced clinicians.
Ethics statement. Studies 1 to 3 were approved by the Gold Coast
Hospital and Health Services District Human Research Ethics Com-
mittee (HREC) and/or the Griffith University HREC. Studies 4 and 5
were approved by the Queensland Institute of Medical Research
(QIMR) HREC. The studies were registered at the Australian New
Zealand Clinical Trials Registry (study 1, ACTRN12612001153808;
study 2, ACTRN12613000615785; study 3: ACTRN12613001187730;
study 4, ACTRN12613000669796 and study 5, ACTRN12612000824864).
Written informed consent was obtained from all of the participants prior
to the commencement of this study.
P. falciparum malaria blood-stage cell banks. For studies 1 to 3,
cultured P. falciparum NF54 (studies 1 and 2) and 7G8 (study 3) malaria
blood-stage cell banks were manufactured at the Institute for Glycomics,
Griffith University, as previously described (41). The P. falciparum 3D7B
cultured malaria blood-stage cell bank (study 4) was manufactured at the
QIMR BerghoferMedical Research Institute as previously described (41);
it was derived from a vial of an ex vivo P. falciparum 3D7 cell bank that has
been used in previous clinical studies (37–40, 42).
The ex vivo P. falciparumHMP02 cell bank (study 5) was derived from
an Australian resident who contracted malaria in Ghana. Parasitized red
blood cells were cryopreserved at the QIMR Berghofer Medical Research
Institute as previously described (43).
Using methodology that has been previously described (43), P. falcip-
arum NF54 blood-stage malaria cell banks (NF54-S01 and NF54-S02)
were prepared from the peripheral blood of both study participants in-
fected with P. falciparumNF54 (study 2) just prior to the commencement
of A/L treatment.
PCR. Sample preparation, DNA extraction, and parasitemiameasure-
ment by quantitative PCR (qPCR)were done as previously described (44),
with the following modifications. A standard curve was prepared from a
lyophilizedWHOP. falciparum international standard (National Institute
for Biological Standards and Control code 04/176) (45) that was reconsti-
tuted in 500l of nuclease-freewater and diluted in a 1:1 solutionwith 1
phosphate-buffered saline (PBS; Gibco). DNAwas isolated from500l of
this solution at a concentration of 5  108 IU/ml. Blood samples from
study participants and standards were tested in triplicate. Established
modified calculations (46) were used to equate international units per
milliliter to parasites permilliliter, with 1 IU/ml equivalent to 0.5 parasite/
ml. The number of parasites per milliliter was calculated with the CFX96
Touch Real Time detection system software (Bio-Rad, Australia).
Measurement of antibodies to the surface of P. falciparum PEs by
flow cytometry. Testing for IgG binding to the surface of PEs by flow
cytometry was performed as described previously (47), with some minor
modifications (see the supplemental material).
Preparation and administration of the parasite inoculum. Inocula
were prepared as previously described, by taking an aliquot of the relevant
cell bank and thawing, washing, and diluting it to the appropriate dose
and volume with 0.9% saline for injection (42). The number of parasites
present in the inoculum was verified retrospectively by qPCR assay of
surplus material. The inoculums were dispensed into as many 2-ml sy-
ringes as required for administration to the study participants who were
inoculated by intravenous injection.
P. falciparum adhesion assays. Adhesion assays were performed as
previously described (48, 49), with P. falciparum trophozoite-stage PEs.
Incubation was at 37°C for 30 min, and washing steps were performed
with RPMI. Bound cells were fixed in 2% glutaraldehyde in PBS, stained
with Giemsa, and counted bymicroscopy. Adhesion to CD36 at 20g/ml
(rhCD36/Fc Chimera; R&D Systems) was tested in triplicate.
Scanning electron microscopy. Scanning electron microscopy was
performed with P. falciparum trophozoite-stage PEs as outlined in the
supplemental material.
kahrp expression assay. The level of kahrp expression in the cell bank
parasites and participant blood was quantified by reverse transcription-
qPCR as outlined in the supplemental material.
Statistical analysis. The R package was used to calculate the Pearson
correlation coefficients for the relative kahrp gene copy number and the
average binding data to CD36.
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RESULTS
To test the infectivity of the NF54 strain of P. falciparum, two
volunteers were inoculated with 1,800 PEs. This number had been
previously used forCHMI studieswith volunteers infectedwith an
ex vivo bank of the 3D7 clone of NF54 (38). Parasites were not
detected by qPCR in the blood of volunteers for up to 10 days (Fig.
1A), at which time participants commenced antimalaria treat-
ment with A/L, in accordance with the study protocol. Sixmonths
later, the same volunteers were reinoculated with 30,000 NF54
PEs. We observed parasites in both individuals on day 6 (Fig. 1B).
Parasite growth kinetics were similar to those previously reported
for ex vivo-initiated infections with 1,800 PEs (38). A/L treatment
was initiated on days 10 and 11. We then tested the infectivity of
three other parasite lines with a dose of 1,800 PEs: a cultured 7G8
line (41), a 3D7 line referred to as 3D7B (41) that had only recently
been cultured from the ex vivo 3D7 bank (43), and a novel ex vivo
parasite, HMP02. The growth curves are shown in Fig. 1C to E.
The parasite growth kinetics were similar to those of 30,000 NF54
PEs (Fig. 1B). No serious adverse events were observed in any
volunteers. Minor adverse events and laboratory abnormalities
are listed in Tables S1 and S2 in the supplemental material.
During the infectivity studies, new parasite isolates were de-
rived directly ex vivo from the peripheral blood of the volunteers
who received 30,000 NF54 PEs (NF54-S01 and NF54-S02) and
from one of the volunteers who received 1,800 3D7B PEs (3D7-
S102). These were used for further studies (described below) that
were performed after six or seven cycles of in vitro culture.
To understand why the infectivity of NF54 was lower, we used
FIG 1 Course of parasitemia in study participants inoculated with P. falciparum cell banks. Shown are the parasite levels in study participants following
inoculation with the different P. falciparum cell bank parasites. (A) Study 1, P. falciparumNF54 (cultured cell bank). (B) Study 2, P. falciparumNF54 (cultured
cell bank). (C) Study 3, P. falciparum 7G8 (cultured cell bank). (D) Study 4, P. falciparum 3D7B (cultured cell bank). (E) Study 5, P. falciparumHMP02 (ex vivo
cell bank). Arrows indicate the times of administration of drug treatment. Note the different y-axis scale for P. falciparum 3D7B. In each study, n 2.
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scanning electronmicroscopy to examine the surface composition
of the PEs for the expression of knobs. A 3D7 parasite line that was
regularly selected by gelatin flotation tomaintain knob expression
was used as a positive control and displayed numerous prominent
knobs on the erythrocyte surface (50) (Fig. 2A). In comparison,
theNF54 PEs exhibited a smooth surface, similar to what has been
observed in kahrp knockout lines (18) (Fig. 2B). Knobs were pres-
ent on the surface of the cultured 3D7B PEs (Fig. 2E), on the P.
falciparum 7G8 PEs (Fig. 2G), on the ex vivo HMP02 PEs (Fig.
2H), and on PEs from the three ex vivo parasite lines (NF54-S01,
NF54-S02, and 3D7-S102) derived from the study participants
(Fig. 2C, D, and F). Thus, infection with NF54 PEs resulted in the
selection of knob-expressing parasites in the two volunteers.
Knobs andPfEMP1play an important role in parasite adhesion
and virulence, with CD36 being an important receptor for
PfEMP1. Thus, we performed static binding assays to examine the
adhesion of PEs from the different parasite lines to CD36. Adhe-
sionwas evaluated relative to that of the same 3D7 control parasite
used to characterize knob expression. No adhesion of P. falcipa-
rum NF54 PEs to CD36 was observed (Fig. 3), whereas adhesion
comparable to that of the 3D7 control was observed in all of the
other parasites. This included ex vivo parasite lines NF54-S01 and
NF54-S02, indicating that in vivo infection with NF54 also altered
the adhesive phenotype of the parasite.
KAHRP is essential for knob formation, and deletion of the
kahrp gene from one end of chromosome 2 has been observed in
long-term-cultured isolates (8). Thus, we examined the levels of
kahrp gene transcription in the parasite lines by qPCR, aiming to
determine if the lack of knobs and CD36 receptor binding by
NF54PEswas due to deletion of the kahrp gene or downregulation
of gene expression. Expression of kahrp was observed in all of the
parasite lines, includingP. falciparumNF54,which did not express
knobs (Fig. 4). There was no relationship between the relative
copy numbers of the kahrp gene present in the parasites and ad-
hesion to CD36 (r0.18; P 0.7).
Using serum samples from adults residing in a region of Papua
New Guinea where malaria is endemic, we examined antibody
recognition of the surface of PEs from the different parasite lines
by flow cytometry. Antibodies to the surface of PEs predomi-
nantly recognize PfEMP1 (50). The 3D7 parasite was again used as
a control. PEs from all of the parasite lines were recognized by the
Papua New Guinea serum samples (Fig. 5; see Fig. S1 in the sup-
plemental material), suggesting that the NF54 PEs continued to
express PfEMP1 and other variant surface antigens. It was of in-
terest that PEs from the ex vivo-derived lines (NF54-S01, NF54-
S02, and 3D7-S102) were not as well recognized by antibodies in
the serum as PEs from the parental parasites with which the vol-
unteerswere infected (NF54, 3D7B), perhaps reflecting a switch to
the expression of a new PfEMP1-encoding gene during infection.
DISCUSSION
Here, using novel P. falciparum cultured and ex vivo-derived
blood-stage cell banks (41), we have demonstrated, for the first
time in malaria-naive individuals, a relationship between knob
expression, cytoadhesion, and the in vivo infectivity of P. falcipa-
rum. This is also the first time that blood-stage parasites from
clinical-grade P. falciparum cultured cell banks (41) have been
administered to human volunteers to evaluate their safety and
infectivity.
Following the administration of 1,800 NF54 PEs to twomalar-
ia-naive study participants, parasite growth was not detected in
their blood up to day 10 postinoculation. We cannot exclude the
possibility that if we had continued to monitor these individuals,
parasites would have been detected. However, the study protocol
required initiation of antimalaria treatment at that time. Limit-
C
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FIG2 Surface characteristics of PEs fromdifferentP. falciparum parasite lines.
Shown are scanning electron micrographs of the P. falciparum 3D7 control
(A), P. falciparum NF54 (cultured cell bank) (B), P. falciparum NF54-S01
(derived ex vivo from S01 at the time of drug treatment) (C), P. falciparum
NF54-S02 (derived ex vivo from S02 at the time of drug treatment) (D), P.
falciparum 3D7B (cultured cell bank) (E), P. falciparum 3D7-S102 (derived ex
vivo from S102 at the time of drug treatment) (F), P. falciparum 7G8 (cultured
cell bank) (G), and P. falciparumHMP02 (ex vivo cell bank) (H). Representa-
tive images are shown, and the scale bars all represent 2 m.
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ing-dilution analysis of this cell bank has demonstrated that the
viability of these parasites is approximately 50% (41), thereby ex-
cluding the possibility that lack of parasite growth was due to
unhealthy/dead parasites. We subsequently administered 30,000
NF54 PEs to the same volunteers and observed parasite growth.
Infectivity was observed for all other cultured and ex vivo-derived
cell banks. In vitro characterization of theNF54 PEs demonstrated
that they lacked knobs and were unable to adhere to CD36 but
were still recognized by antibodies present in the serum of malar-
ia-exposed individuals, suggesting that PfEMP1 and/or other vari-
ant surface antigens were still being expressed. Previous studies
have demonstrated that long-term culture can be associated with
loss of knobs and loss of CD36-mediated cytoadhesion as mea-
sured in vitro (4, 10), as well as in in vivo studies in animal models.
Furthermore, this phenotype is associated with attenuation of
parasitemia in nonsplenectomized monkeys (23). We do not
know when our NF54 cell bank became predominantly knobless
PEs. Prior to drug treatment, new parasite isolates (NF54-S01 and
NF54-S02) were derived ex vivo from the peripheral blood of the
volunteers who received 30,000 NF54 PEs. Knob expression and
CD36-mediated adhesion were observed in PEs from these two
isolates. Recovery of the knobby, cytoadherent phenotype follow-
ing administration to the study participants could reflect that the
NF54 parasite line is not clonal, with a small proportion of PEs still
expressing knobs and able to cytoadhere. With an increased inoc-
ulum dose of 30,000 PEs, it is possible that this minor population
initiated infection by sequestering in the periphery and evading
destruction by macrophages in the spleen. Transcription of the
kahrp gene was detected in cell bank parasites, indicating that the
lack of knob expression was not due to a gene deletion or tran-
scriptional silencing. We cannot exclude the possibility that epi-
genetic reprogramming or deletion of other genes important in
knob formation contributed. As infectivity was observed with the
other cultured banks (7G8 and 3D7B) when 1,800 PEs were ad-
ministered, and knob expression and adhesion were absent from
only NF54, this phenomenon appears to be isolate dependent, as
was previously described in vitro (10).
This is the first study to document the administration of blood-
stage parasites from cultured P. falciparum malaria cell banks di-
rectly to human volunteers. Additionally, it is the first study to
evaluate the safety and virulence of well-characterized, clinical-
grade P. falciparum lines that may be used in CHMI studies to
assess the efficacy of novel antimalaria drugs and vaccines. For all
four of the cell banks tested, the inoculum was well tolerated by
recipients. Until recently, the ability to conduct CHMI studies has
relied on access to clinical-grade sporozoites or P. falciparum-
infected erythrocytes derived directly ex vivo from malaria-
infected individuals. Our recent production of clinical-grade,
cultured P. falciparum blood-stage cell banks (41) offers an addi-
tional approach to CHMI. The use of cultured parasites in CHMI
studies will accelerate the development of novel antimalaria drugs
FIG 3 Binding of P. falciparum PEs from different parasite lines to CD36.
Shown is the adhesion to recombinant CD36 of P. falciparumNF54 (cultured
cell bank) and P. falciparum NF54-S01 and NF54-S02 (derived ex vivo from
S01 and S02 at the time of drug treatment) (top), P. falciparum 3D7B (cultured
cell bank) andP. falciparum 3D7-S102 (derived ex vivo fromS102 at the time of
drug treatment) (middle), and P. falciparumHMP02 (ex vivo cell bank) and P.
falciparum 7G8 (cultured cell bank) (bottom).Values are expressed as percent-
ages of the P. falciparum 3D7 control parasite binding to CD36. Assays were
performed twice independently, and bars represent median values and inter-
quartile ranges of experimental replicates of samples tested in triplicate.
FIG 4 Expression of kahrp in different P. falciparum parasite lines. Shown are
kahrp expression levels in P. falciparum cell bank and ex vivo-derived parasites
relative to those of the single-copy fructose-bisphosphate aldolase gene.
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and malaria vaccine candidates, provided the phenotype and in-
fectivity of the parasites are known.We observed that NF54 infec-
tivity is related to cytoadherence and knob expression. However,
loss of these characteristics is isolate dependent.
In conclusion, by using a novel approach to CHMI, we have
demonstrated that the human environment can directlymodulate
the virulence of P. falciparum by altering the surface phenotype of
PEs. While we have studied a single virulence phenotype, it seems
likely that other virulence phenotypes may also be under selective
pressure from the human host. CHMI with cultured malaria par-
asites provides an exciting opportunity to study malaria patho-
genesis in humans.
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(middle left), P. falciparum 3D7-S102 (derived ex vivo from S102 at the time of
drug treatment) (middle right), and P. falciparum HMP02 (ex vivo cell bank)
(bottom). The IgG binding level is expressed as the geometric mean fluores-
cence intensity (MFI) in all of the graphs, and the bars represent the median
values and interquartile ranges of samples tested in duplicate (n 10 for all P.
falciparum cell banks).Minimal reactivity was observed among serum samples
from nonexposed Melbourne controls.
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